The Evaluation of effectiveness of heparin nebulizer in reduction of respiratory distress in patients with COVID-19

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210513051275N1

Enrollment

Registered

2021-07-06

Start date

2021-08-06

Completion date

Unknown

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: They will be treated with a heparin nebulizer at a dose of 5,000 units every 8 hours. Intervention 2: Intervention group: They will be treated with normal saline (p

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with COVID-19 treated in Yazd In the Summer of 2021, which was proven by radiographic involvement in radiography andThey have respiratory distress and O2 SAT below 90%.

Exclusion criteria

Exclusion criteria: Patients treated with anticoagulants Patients with a variety of coagulation disorders Patients who have impaired coagulation tests at initial evaluation. Patients with proven cardiovascular disease Patients taking medications that interfere with the medications we use. Patients with severe COVID-19 who require ICU admission and mechanical ventilation prior to intervention. Patients who do not have clear lung involvement on radiography and respiratory distress.

Design outcomes

Primary

Measure	Time frame
Number of breaths. Timepoint: Before the intervention and three days after the start of the intervention. Method of measurement: Cardiac device for monitoring and recording information in a questionnaire.;Percentage of arterial blood oxygen saturation (SpO2). Timepoint: Before the intervention and three days after the start of the intervention. Method of measurement: Pulse oximetry of cardiac monitoring device and recording information in a questionnaire.;Patient body temperature. Timepoint: Before the intervention and three days after the start of the intervention. Method of measurement: Digital thermometer (forehead temperature measurement).;Severity of lung involvement. Timepoint: Before the intervention and three days after the start of the intervention. Method of measurement: Radiographic device.;Severe shortness of breath. Timepoint: Before the intervention and three days after the start of the intervention. Method of measurement: Patient self-declaration.	—

Measure

Time frame

Number of breaths. Timepoint: Before the intervention and three days after the start of the intervention. Method of measurement: Cardiac device for monitoring and recording information in a questionnaire.;Percentage of arterial blood oxygen saturation (SpO2). Timepoint: Before the intervention and three days after the start of the intervention. Method of measurement: Pulse oximetry of cardiac monitoring device and recording information in a questionnaire.;Patient body temperature. Timepoint: Before the intervention and three days after the start of the intervention. Method of measurement: Digital thermometer (forehead temperature measurement).;Severity of lung involvement. Timepoint: Before the intervention and three days after the start of the intervention. Method of measurement: Radiographic device.;Severe shortness of breath. Timepoint: Before the intervention and three days after the start of the intervention. Method of measurement: Patient self-declaration.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contact?Dr.Maryam Tavakoli

Islamic Azad University

shohadakargar.hos@tamin.ir+98 35 3825 4040

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026